EP1608395A4 - Anticancer agent comprising lk8 protein as an active ingredient - Google Patents

Anticancer agent comprising lk8 protein as an active ingredient

Info

Publication number
EP1608395A4
EP1608395A4 EP04713257A EP04713257A EP1608395A4 EP 1608395 A4 EP1608395 A4 EP 1608395A4 EP 04713257 A EP04713257 A EP 04713257A EP 04713257 A EP04713257 A EP 04713257A EP 1608395 A4 EP1608395 A4 EP 1608395A4
Authority
EP
European Patent Office
Prior art keywords
protein
active ingredient
anticancer agent
anticancer
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04713257A
Other languages
German (de)
French (fr)
Other versions
EP1608395A1 (en
Inventor
Hyunkyung Yu
Jang-Seong Kim
Jin-Hyung Ahn
Ho-Jeong Lee
Kwan-Yub Kang
Hyung-Kwon Lim
In-Hwan Lim
Sung Geun Kim
Hak Kyu Joo
Jihyun Lee
Yeup Yoon
Doo-Hong Park
Jung Hwan Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Publication of EP1608395A1 publication Critical patent/EP1608395A1/en
Publication of EP1608395A4 publication Critical patent/EP1608395A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04713257A 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient Withdrawn EP1608395A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2003010797 2003-02-20
KR1020030010797A KR100595364B1 (en) 2003-02-20 2003-02-20 Anticancer agent comprising LK8 protein as an active ingredient
PCT/KR2004/000357 WO2004073730A1 (en) 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient

Publications (2)

Publication Number Publication Date
EP1608395A1 EP1608395A1 (en) 2005-12-28
EP1608395A4 true EP1608395A4 (en) 2007-10-31

Family

ID=36116045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04713257A Withdrawn EP1608395A4 (en) 2003-02-20 2004-02-20 Anticancer agent comprising lk8 protein as an active ingredient

Country Status (9)

Country Link
EP (1) EP1608395A4 (en)
JP (1) JP2006518342A (en)
KR (1) KR100595364B1 (en)
CN (1) CN100546646C (en)
AU (1) AU2004212856B2 (en)
BR (1) BRPI0407611A (en)
CA (1) CA2516172A1 (en)
RU (1) RU2306147C2 (en)
WO (1) WO2004073730A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285277B2 (en) 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
CN1946430B (en) * 2004-01-09 2012-03-21 财团法人牧岩生命工学研究所 Therapeutic agent for treatment of cancer comprising human apolipoprotein (A) kringles LK68 or LK8 genes as effective ingredient, and method for treating cancer using the same
RU2006145886A (en) 2004-06-25 2008-06-27 Такеда Фармасьютикал Компани Лимитед (Jp) DERIVATIVES METASTINE AND THEIR APPLICATION
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (en) 2005-12-22 2008-02-13 Takeda Pharmaceutical METASTININE DERIVATIVES AND USE OF THE SAME
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
KR100888022B1 (en) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion Proteion of Imunoglobulin Fc and Human Apolipoproteina Kringle Fragment
ES2565512T3 (en) 2007-07-19 2016-04-05 bioMérieux Test procedure for liver fatty acid binding protein, ACE and CA19-9 for in vitro diagnosis of colorectal cancer
FR2919064B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF ASSAYING APOLIPOPROTEIN ALL FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919065B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD FOR DETERMINING APOLIPOPROTEIN AI FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919060B1 (en) 2007-07-19 2012-11-30 Biomerieux Sa METHOD OF DETERMINING EZRINE FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
FR2919062B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING AMINOACYLASE 1 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919063B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DETERMINING LEUCOCYTE ELASTASE INHIBITOR FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2919061B1 (en) 2007-07-19 2009-10-02 Biomerieux Sa METHOD OF DOSING PLASTINE-I FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER.
FR2933773B1 (en) 2008-07-10 2013-02-15 Biomerieux Sa METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
WO2012067427A2 (en) * 2010-11-16 2012-05-24 재단법인 목암생명공학연구소 Pharmaceutical composition containing lk8 protein as an active ingredient for preventing or treating diabetic retinopathy or age-related macular degeneration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3725473B2 (en) * 1999-09-15 2005-12-14 モーガン バイオテクノロジー リサーチ インスティテュート Novel angiogenesis inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KIM J-S ET AL: "Human apolipoprotein(a) kringle V inhibits angiogenesis in vitro and in vivo by interfering with the activation of focal adhesion kinases", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 313, no. 3, 16 January 2004 (2004-01-16), pages 534 - 540, XP004481590, ISSN: 0006-291X *
KIM J-S ET AL: "Inhibition of angiogenesis and angiogenesis-dependent tumor growth by the cryptic kringle fragments of human apolipoprotein(a)", JOURNAL OF BIOLOGICAL CHEMISTRY 01 AUG 2003 UNITED STATES, vol. 278, no. 31, 1 August 2003 (2003-08-01), pages 29000 - 29008, XP002450345, ISSN: 0021-9258 *
See also references of WO2004073730A1 *
XUE S ET AL: "Apo(a) kringle V inhibits endothelial cell proliferation", FIBRINOLYSIS AND PROTEOLYSIS, vol. 14, no. Supplement 1, June 2000 (2000-06-01), & XVTH INTERNATIONAL CONGRESS ON FIBRINOLYSIS AND PROTEOLYSIS; HAMAMATSU, JAPAN; JUNE 25-29, 2000, pages 35, XP008083595, ISSN: 1369-0191 *
YU H-K ET AL: "Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles", CANCER RESEARCH 01 OCT 2004 UNITED STATES, vol. 64, no. 19, 1 October 2004 (2004-10-01), pages 7092 - 7098, XP002450346, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
EP1608395A1 (en) 2005-12-28
WO2004073730A1 (en) 2004-09-02
AU2004212856B2 (en) 2007-07-19
CN1753685A (en) 2006-03-29
CN100546646C (en) 2009-10-07
KR20040075270A (en) 2004-08-27
RU2005129273A (en) 2006-03-10
RU2306147C2 (en) 2007-09-20
CA2516172A1 (en) 2004-09-02
JP2006518342A (en) 2006-08-10
AU2004212856A1 (en) 2004-09-02
BRPI0407611A (en) 2006-02-14
KR100595364B1 (en) 2006-07-03

Similar Documents

Publication Publication Date Title
HUS2200020I1 (en) Synergistic fungicidal active substance combinations
EP1631239A4 (en) Pharmaceutical compositions comprising active vitamin d compounds
PL374390A1 (en) Fungicidal active substance combinations
EP1622540A4 (en) Formulations for cell- schedule dependent anticancer agents
ZA200604352B (en) Azepinondole derivatives as pharmaceutical agents
PL372084A1 (en) 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
GB0323908D0 (en) Pharmaceutical foam formulation
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
IL173808A0 (en) Pharmaceutical liposomal formulations
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
IL172824A0 (en) Pharmaceutical formulations
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
GB0302671D0 (en) Pharmaceutical formulations
EP1608395A4 (en) Anticancer agent comprising lk8 protein as an active ingredient
HK1090546A1 (en) Dosage form containing pantoprazole as active ingredient
HK1105202A1 (en) Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
IL174135A0 (en) Benzimidazole acetonitrile derivatives, their preparation and and pharmaceutical compositions containing them
GB0316206D0 (en) Pharmaceutical formulation
GB0318448D0 (en) Formulation
GB0302672D0 (en) Pharmaceutical formulations
GB0312195D0 (en) Formulation
GB0316341D0 (en) Pharmaceutical formulations
GB0320522D0 (en) Formulation
GB0326221D0 (en) Therapeutic agents,compositions,preparations and uses
AU2003259532A1 (en) Ready-to-drink formulation containing an active ingredient

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050919

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20070919BHEP

Ipc: A61P 35/04 20060101ALI20070919BHEP

Ipc: A61K 38/17 20060101AFI20070919BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20071002

17Q First examination report despatched

Effective date: 20100730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130903